
PASSAGE BIO (PASG) Stock Forecast & Price Target
PASSAGE BIO (PASG) Analyst Ratings
Bulls say
Passage Bio is primarily focused on developing cutting-edge, one-time gene therapies to target neurodegenerative diseases, making it a valuable asset in this sector. However, the discontinuation of a similar program by Eli Lilly due to efficacy concerns raises potential regulatory hurdles and risks for Passage Bio, which could impact attainment of its projected price target and overall rating.
Bears say
Passage Bio is at a critical point in its development, with the recent safety issues in its lead programs casting doubt on the company's ability to advance its pipeline. Additionally, the high valuation of the company, with a price target of $8 per share, reflects the risks and uncertainties surrounding its development and commercialization strategy. Furthermore, the competitive landscape in the neurodegenerative disease market poses a significant threat to Passage Bio's success.
This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.
PASSAGE BIO (PASG) Analyst Forecast & Price Prediction
Start investing in PASSAGE BIO (PASG)
Order type
Buy in
Order amount
Est. shares
0 shares